Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 1988 Jan;47(1):43-7
Date
01/01/1988Pubmed ID
2449871Pubmed Central ID
PMC1003442DOI
10.1136/ard.47.1.43Scopus ID
2-s2.0-0023870044 (requires institutional sign-in at Scopus site) 93 CitationsAbstract
Iloprost, a stable prostacyclin analogue, was given by intravenous infusion to 29 patients with severe Raynaud's phenomenon, 26 of whom had systemic sclerosis (SS), and compared with placebo infusion in a double blind crossover trial. Iloprost significantly lessened the number and the severity of attacks compared with placebo. Nine patients expressed a preference for effectiveness of treatment, eight of these in favour of Iloprost. Thermography failed to show any long term effect of Iloprost. Side effects of headache, flushing, nausea, and vomiting were common, and the inconvenience of intravenous administration may limit its routine use.
Author List
McHugh NJ, Csuka M, Watson H, Belcher G, Amadi A, Ring EF, Black CM, Maddison PJAuthor
Mary Ellen Csuka MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Clinical Trials as TopicDouble-Blind Method
Epoprostenol
Female
Humans
Iloprost
Injections, Intravenous
Male
Raynaud Disease
Scleroderma, Systemic
